Aehr Test (AEHR) Q2 2025 Earnings Call Transcript

Revenue declined 37% YoY to $13.5M in Q2; non-GAAP gross margin fell to 45.3% from 51.6% and non-GAAP net income dropped to $0.7M ($0.02/sh) from $6.7M a year ago. Bookings were $9.2M in-quarter plus $14.2M in the first six weeks post-quarter for an effective backlog of $26.6M; WaferPak revenue was $8.6M (64% of revenue). Cash and restricted cash stood at $35.2M with no debt and an SEC-approved $400M S-3 shelf; management secured first production orders for AI processors and GaN, integrated Incal products, and reaffirmed FY guidance of at least $70M revenue and >=10% non-GAAP pre-tax margin. Key near-term risks include ongoing silicon carbide market softness, elevated legal costs from a China IP lawsuit and U.S. litigation, and quarterly revenue timing volatility.

Analysis

Aehr’s real optionality is not a single large system sale but the combo of wafer-level contact technology plus high‑power package capability: that creates an installed base that sells high-margin consumables and forces OSATs/IDMs to rewire test flows. If AI/HBM and compound‑semiconductor ramps follow their directional trajectories, demand for front‑loaded wafer screening will compress downstream scrap rates and increase customer willingness to pay for full‑wafer solutions — a structural margin lever that’s usually under‑modeled by sell‑side cycle math.

The dominant near‑term tail risks are binary execution and jurisdictional enforcement. Delays converting pre‑built systems into revenue, higher legal/defense spend, or restricted access to a large regional customer base could turn lumpy backlog into multi‑quarter writeoffs; conversely, smooth OSAT deployments and rapid consumable pullthrough would convert a discrete systems business into recurring revenue within 6–18 months. Operationally, integration of a packaged‑part product line will pressure reported margins until manufacturing and service footprints are rationalized.

Consensus underweights two secondary effects: (1) a successful wafer‑level solution will force customers to reallocate part of their ATE budget away from traditional single‑die test toward parallel, high‑power wafer‑level equipment (reshuffling, not eliminating, ATE spend), and (2) OSAT endorsement acts as a distribution multiplier — one large OSAT win can create a multi‑customer funnel in months, not years. That asymmetry (fast funnel vs slow legal drag) creates an attractive asymmetric payoff for defined‑risk instruments sized small relative to total exposure.

Key Decisions for Investors

• Small, defined‑risk long on AEHR (size 0.5–1.5% portfolio): buy 12–18 month call spreads to capture potential outsized upside from OSAT rollouts and consumable annuity. Rationale: limited premium at risk; reward if multiple production installs announce pull‑through. Watch catalysts: first public OSAT production deployments and 2–3 quarterly prints showing consumable revenue conversion.
• Hedge operational/legal binary with a collar: if owning stock, sell a near‑term covered call and buy a 9–12 month protective put to cap downside from jurisdictional/legal shocks or an opportunistic equity raise. This preserves upside from product adoption while limiting tail loss from execution/geo risks.
• Relative‑value pair (small size): long AEHR / short a broad ATE incumbent (e.g., TER) to express asymmetric niche share gains in wafer‑level and ultra‑high‑power segments. Rationale: Aehr’s specialization benefits from AI/HBM structural demand while broad incumbents trade on diversified cycles. Timeframe 6–12 months; max drawdown if market widens in ATE cyclicality.
• Event‑driven tactical: accumulate on post‑quarter weakness after visible OSAT ship confirmations (sell‑side timing window). If legal headlines turn adverse, trim quickly and redeploy into LEAP calls on any 20–30% pullback — preserves optionality while respecting visibility risk.